Somaxon (SOMX) Rips Higher Following FDA Meeting on Silenor OTC Program
Tweet
Share
E-mailGet Alerts SOMX Hot Sheet
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), is ripping higher Tuesday morning, following an announcement it met with the U.S. FDA relating to the over-the-counter (OTC) development program for Silenor. In the meeting, which Somaxon attended jointly with its Silenor partner Procter & Gamble (NYSE: PG), the FDA provided clinical and regulatory guidance that the company believes provides a clear path forward toward an OTC version of Silenor.
The stock is up nearly 44 percent on the news.
The stock is up nearly 44 percent on the news.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
